AMS Stock Overview
Provides stereotactic radiosurgery and advanced radiation therapy equipment.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
American Shared Hospital Services Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$3.69 |
| 52 Week Low | US$2.16 |
| Beta | 0.70 |
| 11 Month Change | -2.74% |
| 3 Month Change | 0.95% |
| 1 Year Change | 21.60% |
| 33 Year Change | 10.73% |
| 5 Year Change | 9.59% |
| Change since IPO | 28.00% |
Recent News & Updates
Shareholder Returns
| AMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.6% | 0.5% | -2.4% |
| 1Y | 21.6% | 5.7% | 17.5% |
Return vs Industry: AMS exceeded the US Healthcare industry which returned 4.7% over the past year.
Return vs Market: AMS exceeded the US Market which returned 17.2% over the past year.
Price Volatility
| AMS volatility | |
|---|---|
| AMS Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMS has not had significant price volatility in the past 3 months.
Volatility Over Time: AMS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 31 | Ray Stachowiak | ashs.com |
American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia.
American Shared Hospital Services Fundamentals Summary
| AMS fundamental statistics | |
|---|---|
| Market cap | US$20.76m |
| Earnings (TTM) | US$541.00k |
| Revenue (TTM) | US$21.62m |
37.4x
P/E Ratio0.9x
P/S RatioIs AMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMS income statement (TTM) | |
|---|---|
| Revenue | US$21.62m |
| Cost of Revenue | US$7.02m |
| Gross Profit | US$14.59m |
| Other Expenses | US$14.05m |
| Earnings | US$541.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.085 |
| Gross Margin | 67.51% |
| Net Profit Margin | 2.50% |
| Debt/Equity Ratio | 68.2% |
How did AMS perform over the long term?
See historical performance and comparison